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Case presentation
A 33-year-old man with chronic renal failure due to glomerulonephritis
was referred to the Jinling Hospital because of severe anemia, anorexia,
nausea, and weakness during the preceding 2 months. Ten years ago, he
was diagnosed as having chronic nephritis with proteinuria, hematuria,
and edema. Renal biopsy performed 8 years ago revealed mesangial IgA
nephropathy with marked glomerulosclerosis. He received corticosteroids
and dipyridamole for 8 months without apparent effect. For the past 7
years, he had been told that his serum creatinine and BUN levels were
increased above normal and that his blood pressure had reached 170/120
mm Hg. He was advised by his doctor to eat a low-protein and low-salt diet
and was prescribed antihypertensive and diuretic medications. Proteinuria
persisted, the anemia and hypertension worsened, and he experienced
frequent attacks of dizziness accompanied by nausea and vomiting.
Physical examination revealed a slender, undernourished man; his
height was 175 cm and weight 53 kg. His blood pressure was 180/110 mm
Hg. Funduscopic examination showed narrowing of retinal arterioles.
Cardiac examination disclosed a precordial thrust and a grade Il/Ill apical
systolic murmur. He had mild pedal edema; the physical examination
otherwise was unremarkable.
Serum biochemistry values were: blood urea nitrogen, 65 mg/dl; serum
creatinine, 6.4 mg/dl; creatinine clearance, 13 mI/mm; sodium, 142 mEq/
liter; potassium, 3.8 mEq/liter; chloride, 110 mEq/liter; calcium, 8.0 mg/dl;
phosphorus, 4.6 mg/dl; bicarbonate, 24 mEq/liter; uric acid, 11.9 mg/dl;
alkaline phosphatase, 68 U/liter; triglycerides, 99 mg/dl; and cholesterol,
192 mg/dl. His hematocrit was 25%, and the white blood cell count and
platelet count were normal. The blood pH was 7.33. Urinalysis revealed
the following: pH, 5.2; protein, 2.82 g/24 hr; red blood cell count,
0-2/high-power field. Electrocardiogram showed mild left-ventricular hy-
pertrophy with abnormal T-waves. A chest radiograph revealed no
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apparent cardiac abnormalities. Renal ultrasound showed the left kidney
to be 8.2 cm and the right 7.8 cm long.
A low-protein diet providing 0.6 g/kg of high-quality protein was
prescribed with an emphasis on low-phosphate foods. His medications
included captopril, 25 mg three times daily, and nifedipine, 10 mg three
times daily; these kept his blood pressure at 130/80 mm Hg. Sodium
bicarbonate, 1.0 g three times daily, was given for one month to correct the
mild acidosis. In addition, extract of rhubarb, 3 g three times daily, was
served throughout the course of treatment. The patient improved progres-
sively and was free of symptoms 2 months after the treatment was begun.
His appetite returned to normal.
Over the past 5 years, the patient's prescribed regimen has been rhubarb
and antihypertensive medication. He was not fully compliant with the
dietary regimen, as he experienced weakness when he followed the diet
strictly. He had regular followup examinations and has been hospitalized
twice for thorough examinations. He remains asymptomatic. Values for
serum creatinine, BUN, and plasma proteins during the past 51 months
are shown in Figure 1.
Discussion
DR. LEISHI LI (Professor and Director, Research Institute of
Nephrology, Jinling Hospita4 Nanjing University School of Medicine,
Nanjing, China): This man presented with a history of nephrotic
syndrome accompanied by hematuria and hypertension; his renal
function progressively deteriorated, and the serum creatinine
eventually rose to 6.0 mg/dl when he was admitted to our hospital.
His clinical features and outcome are consistent with the renal
biopsy findings of IgA nephropathy. The presence of marked
glomeruloscierosis, interstitial fibrosis, mononuclear cell infiltra-
tion, and extensive tubular atrophy in the renal biopsy specimen
from this patient predicted a poor prognosis [1]. IgA nephropathy
is the most frequent type of chronic glomerular disease in China;
it is also the most important cause of end-stage renal disease
(ESRD) in my country [2, 3]. This case, one example of the course
and features of severe renal failure in China, describes our usual
medical practice applied to patients with nearly total loss of renal
function.
China, a developing country of 1.1 billion people, has an annual
gross domestic product (GDP) per capita of only 400 US dollars.
The nationwide statistics on the ESRD population are not
available yet. According to an epidemiologic survey of 2,000,000
residents of urban and suburban areas around Nanjing, the
prevalence of ESRD is about 568/million. For men, it is 485/
million, and for women, 620/million; the highest prevalence
occurs in the 5th to 6th decade of life (unpublished observation).
Table 1 shows the common causes of end-stage renal disease in
China and the proportional distribution of each of these under-
lying diseases in cases admitted to our institute over the 10-year
period 1984—1993. Glomerulonephritis constituted the most fre-
quent cause (48.1%); diabetic nephropathy accounted for only
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4.7%, while interstitial nephritis and hypertension caused 6.2%
and 7.1% of all cases, respectively. Geographic variations play a
part in the distribution of different diseases leading to ESRD and
might partially be reflected by the economic development of each
local region. Generally, glomerulonephritis is more prevalent in
the less-developed regions. With the industrialization of society,
the prevalence of diabetic renal disease increases. As compared
with the figures from western countries, the prevalence of glomer-
ulonephritis as the chief cause of ESRD in China is very striking
(Fig. 2) [4, 51.
Among 152 consecutive patients with ESRD admitted to our
institute who had a history of glomerulonephritis and who had
undergone renal biopsy, IgA nephropathy was the most frequent
underlying disease (38.2%), followed by focal segmental glomerulo-
sclerosis (FSGS) (26.3%), crescentic glomerulonephritis (9.2%),
and membranoproliferative glomerulonephritis (MPGN) (8.6%).
In this series, membranous nephropathy and mesangial prolifer-
ative glomerulonephritis caused ESRD only occasionally (Table
2).
In China, ESRD is characterized by a high frequency of severe
anemia. As Table 3 illustrates, 97.2% of the patients had anemia
(hemoglobin < 12 gldl); in 76.4%, the hemoglobin was less than
6 gldl. In contrast, the statistics from Europe indicate that it is rare
for the hemoglobin level to fall below 5 g/dl in adults in chronic
renal failure who are not on dialysis [6]. Hypertension is also
frequent (84.2%) in Chinese patients with ESRD. Although
uremic pericarditis (18.3%) and hypoproteinemia (19.0%) are
becoming less frequent than before, they remain important clin-
ical problems. The frequent occurrence of these severe uremic
manifestations in our ESRD patients reflects the lack of appro-
priate treatment at an earlier stage for the majority of our patients
with chronic renal failure, particularly the earlier use of renal
replacement therapy.
Treatment modalities
Replacement therapy. Dialysis and kidney transplantation were
introduced to China in the 1960s [3]. Maintenance hemodialysis
Number
of cases %
Chronic renal failure, etiology uncertain 135 12.6
Glomerulonephritis 516 48.1
Histologic diagnosis 156 14.6
Clinical diagnosis 360 33.5
Interstitial nephritis 67 6.2
Hypertension 76 7.1
Diabetic nephropathy 50 4.7
Polycystic kidney disease 26 2.4
Hyperuricemia 15 1.4
Obstructive nephropathy 14 1.3
Hereditaiy nephritis 10 0.9
Vasculitides 10 0.9
Lupus nephritis 9 0.8
Miscellaneous 144 13.4
(HD) for ESRD was not initiated until 1972, however. In 1982,
196 hospitals were equipped with dialysis machines, and approx-
imately 1500 patients were being treated by HD. The number of
dialysis units has grown rapidly from 245 in 1984 to 305 in 1987;
in the early 1990s, the number had reached 400. The total number
of dialysis machines now exceeds 5000. Our best estimate is that
15,000 to 17,000 patients are maintained on hemodialysis; most of
the dialysis units are small and have only a few machines.
Currently, there are six dialysis centers in Beijing, Nanjing,
Guangzhou, and Shanghai, where more than 15,000 dialysis
treatments are performed annually.
Hemodialysis for patients with ESRD is one of the most
expensive medical treatments in China. During 1993—1994, one
HD treatment cost 435 yuan (50 US dollars), a huge economic
burden for most Chinese citizens, where the average income for
urban employees is less than 5000 yuan (574 US dollars) per year.
As a result, most of the patients receiving maintenance dialysis are
government employees or workers of large enterprises (including
only a minor portion of private business owners) who have
medical insurance.
The decision to begin hemodialysis is based on the medical
judgment of the attending physician and the ability of the
individual patient to pay. To reduce expenses, reuse of hemofilters
is a very common and widespread practice. In general, most
patients are dialyzed only when the uremic syndrome has reached
an advanced stage, with creatinine clearance (Ccr) less than
10 ml/min or even 5 ml/min, anemia, vomiting, hyperkalemia,
pericarditis, and oliguria. Both bicarbonate and acetate dialysis
are commonly used, and some patients are dialyzed only twice
weekly for a total of 8 to 9 hours.
Continuous ambulatory peritoneal dialysis (CAPD), introduced
in 1979, was rapidly adopted throughout China because of its
simplicity and easy availability [3]. Modified Tenckhoff catheters
and dialysate bags, locally produced in Shanghai, Nanjing, and
Tianjing, were widely used in the early 1980s with comparatively
low cost, but the occurrence of a high frequency of peritoneal
infection hindered the development of this technique. One report
from Nanjing stated that only 51.8% of the patients remained on
CAPD for more than 2 years [3]. Since 1990, the introduction of
imported devices such as the 0-set and Spike System have
lowered the incidence of peritonitis of CAPD patients and have
-
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Table 1. Causes of ESRD in China (1984—1993)
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Fig. 1. Patient's course over the 5] months offollowup. Time is depicted in
months on the horizontal axis, and serum creatinine (Scr) and BUN on the
vertical axis. Plasma protein values were as listed.
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Fig. 2. Primaiy renal diseases leading to end-
stage renal disease—a comparison between US
(and China (U). Data from the US taken
from the USRDS, 1988; data from China taken
from the Jinhing Hospital.
Table 2. Histologic diagnosis of 152 cases of ESRD (1984—1993)
Number
of cases %
IgA nephropathy 58 38.2
Focal segmental glomerulosclerosis 40 26.3
Glomerulosclerosis 18 11.8
Membranoproliferative glomerulosclerosis 13 8.6
Crescentic glomerulonephritis 14 9.2
Membranous glomerulonephritis 5 3.3
Mesangial proliferative glomerulonephritis 4 2.6
re-attracted the interest of nephrologists, yet their use is still
limited owing to the high cost of the imported equipment.
The first renal transplant in China was performed in Beijing in
1960 [3]. By the mid-1980s, the total number of renal transplants
performed exceeded 1300. Immunosuppressive treatment with
cyclosporine was introduced into my country in 1986, and it
stimulated the development of transplantation work. By the end
of 1993, the cumulative number of renal transplants in China had
reached 12,239. In 1993, 2160 patients with ESRD had received
renal allografts. The annual increase in the rate of kidney
transplantation in China is shown in Figure 3. The one-year graft
survival rate, approximately 50% before the cyclosporine era, now
has risen to more than 85% (Fig. 4). However, long-term results
are still not optimal. Most renal transplants were performed
without HLA matching; more than 90% were cadaveric grafts.
Infection is the most important postoperative complication, par-
ticularly pulmonary infection [7].
Conservative treatment. The meager financial resources of
ESRD patients in China limit their choice of treatment. Both
dialysis and transplantation are very expensive treatments for
people whose GDP per capita is only 400 US dollars. The annual
expenditure for hemodialysis per patient in China is on average
55,000 yuan (6321 US dollars) per year; the initial cost for renal
transplantation amounts to 70,000 yuan (8046 US dollars) per
year. Therefore, the majority of ESRD patients (95%) must seek
a less expensive mode of treatment. Accordingly, conservative,
non-dialytic treatment is the most widely used type of treatment
for ESRD in China. Prevention of the progression of chronic
renal failure is attempted via a low-protein, low-phosphate diet,
and angiotensin-converting-enzyme (ACE) inhibitors are widely
used with measures to control problems such as acidosis, electro-
lyte imbalance, and anemia. Traditional Chinese medicine is also
used frequently in combination with modern medical techniques.
Table 3. Clinical manifestations of ESRD
Clinical manifestation %
Anemia (g/dl)
Hb < 12 97.2
Hb<6 76.4
Hb<4 7.3
Hypertension 84.2
Nocturia 85.6
GI disturbances 81.5
Cardiovascular abnormalities 52.4
Uremic pericarditis 18.3
Neurologic manifestations 11.6
Acidosis 66.5
Hyperkalemia 28.9
Hematuria 11.0
Frank edema 7.0
Hypoproteinemia 19.0
Massive proteinuria 7.0
Customarily, Chinese people used to consume large amounts of
rice or wheat flour as their chief source of caloric intake in daily
foods. Thus, the amount of vegetable protein ingested by the
ESRD patient every day constitutes an important portion of the
daily protein intake and is not likely to be decreased. Supplies of
protein-free cereals are scanty in this country and usually taste
unpleasant even when available. On the other hand, animal
protein intake for the Chinese is usually much lower than for
Westerners, accounting for only 16% of the total amount of
protein consumed, as compared with 32.8% for Westerners. A
rigid regimen of low-protein foods thus is prone to cause malnu-
trition in Chinese patients with ESRD, just as in the man I
presented here. In this case, the patient developed malnutrition
with hypoalbuminemia, a decrease in body weight, and an in-
creased degree of edema when he underwent a strict low-protein
diet (<0.6 glkglday) for 24 months. Later, as he resumed his daily
protein intake at a higher level, his nutritional status improved.
Recently, the United States Modification of Diet in Renal Disease
(MDRD) study recommended that for patients with GFR <35
ml/min/1.73 m2, dietary protein and energy intake are generally
lower, as are indices of nutritional status, than in patients with
higher GFR [8]. In these patients, nutritional status, protein, and
energy intake should be monitored regularly (for example, every
3 months) [9]. Protein intake should be estimated from urine urea
nitrogen excretion, and energy intake should be estimated from
dietary records. Nutritional status is assessed from changes in
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Fig. 3. Cumulative number of renal transplants
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Fig. 4. One-year renal graft (R) and patient (Lii) survival rate in China,
1970 —1990.
weight and serum levels of albumin and transferrin. For patients
with a progressive decrease in body weight, in whom energy intake
is <25 kcal/kg/day and/or protein intake <0.6 g!kg/day, protein
and energy intake should be increased to achieve these levels. If
after achieving these levels of protein and energy intake, body
weight does not increase, energy intake should be increased to
30—35 kcal/kg/day. If this is not possible or unsuccessful, then
protein intake should be raised to 0.75 g/kg/day. For those with
stable body weight, but serum albumin concentration <4.0 g/dl or
serum transferrin concentration <200 mg/dl repeatedly, protein
and energy intake should be raised. For patients with symptoms of
renal failure, but without evidence of malnutrition, protein intake
should be restricted to 0.6 glkg/day and energy intake maintained
at 25 kcal/kg/day.
Angiotension-converting-enzyme inhibitors and calcium-chan-
nel blockers are widely used in China's renal clinics. As in the
West, systemic hypertension is present in most of our patients
with ESRD. Consequently, control of systemic hypertension is
essential for virtually every patient. Many authors support the
statement that adequate blood pressure control is an important
and effective tool for retarding the deterioration of renal function
in patients with chronic renal failure, despite the fact that
well-controlled, prospective, and randomized trials concerning
this subject are lacking. Various antihypertensive drugs have been
used in treating hypertension in ESRD. There is evidence that
ACE inhibitors are more effective than other drugs in arresting
the decline in renal function and in the reduction of proteinuria in
animal models. Therefore, these drugs are used preferentially in
my country [10—13].
A disadvantage of the use of ACE inhibitors in patients with
chronic renal failure might be hyperkalemia, or an abrupt reduc-
tion in the glomerular filtration rate [14]. Another issue in dispute
is, at which blood pressure level should the patient be treated?
The United States MDRD study has made recommendations that
seem to be useful for clinical practice. Hypertension in patients
with chronic renal failure should be controlled at a level of
130/80—85 mm Hg. In patients with chronic renal insufficiency and
proteinuria >1 g/24 hours, the mean blood pressure should be
reduced further to 92 mm Hg (equivalent to 125/75 mm Hg) for
patients with no contraindications to such a low blood pressure
level (for example, cerebrovascular disease) [9].
Traditional Chinese medicine. Traditional Chinese medicine in
the form of herbal decoctions has been used extensively in the
treatment of uremic patients for many years and remains the
cornerstone of treatment in rural areas [3, 15]. The treatment
objective is the elimination of nitrogenous products through the
alimentary canal and the regulation of water and electrolyte
metabolism. Some patients with a moderate degree of renal
failure have been maintained successfully by these conservative
methods for years. However, in patients with severe renal failure,
that is, a serum creatinine level higher than 7 mg/dl, the thera-
peutic response to herbal medicine has been poor. In the past,
herbal medicine has been prescribed for ESRD on an exclusively
empiric basis. Strenuous efforts have been made in recent years to
screen the effectiveness and therapeutic action of various individ-
ual herbs, for example, Salvial miltiorrhizae and rhubarb, isolated
from the decoction. Rhubarb (Rheum officinale), a Chinese herb
used as a laxative for many years in traditional Chinese medicine,
has been found of value in preventing the progression of chronic
renal failure. In this Forum, I will briefly review the basic studies
and clinical research conducted in our institute in recent years,
including cell culture and molecular biology studies, animal
experimentation, and clinical trials.
Chemical studies on rhubarb have been performed extensively
by many investigators over the last 3 decades [16—21]. The root of
the rhubarb plant is cut into slices to make decoctions. Chemical
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and biologic studies on rhubarb have elucidated the active com-
ponents in the plant, and the mechanism of the laxative activity
has been shown to be due to sennoside, a particular ingredient in
rhubarb. Many other ingredients having different pharmacologic
actions have been isolated from the root of rhubarb, among which
anthraquinone and tannins are the most important [16, 21].
Tannins. Japanese workers have extensively studied the tannins
extracted from rhubarb [22—27]. Nishioka isolated more than 50
different tannins from rhubarb; 5 of these have been examined for
their effects in uremic rats on the blood levels of urea nitrogen
(BUN), methyl guanidine (MG), and guanidinosuccinic acid
(GSA) [21]. Blood levels of MG, GSA, BUN, and serum creati-
nine significantly decreased after the administration of (-)epicat-
echin 3-0-gallate at a dose of 5 or 10 mg/kg body weight/day for
24 days [211. A similar but lesser effect occurred with procyanidin
B-2 3 3'-di-O-gallate, but rhatannin, another tannin derivative,
tended to increase the serum nitrogen constituents [211. These
findings led to the suggestion that rhubarb extract might delay the
progression of renal failure [24]. However, no other report has
confirmed these findings or supported the suggestion.
In -vitro studies of emodin
Anthraquinones. Anthraquinones are important constituents of
rhubarb (Fig. 5). More than 20 kinds of anthraquinones have been
isolated, among which emodin, (3-methyl-1,6,8-carboxyl-anthra-
quinone), rhein, and aloe-emodin have been the most extensively
studied by Chinese investigators [28—321.
The effect of emodin on the growth and metabolic changes of
renal mesangial and tubular epithelial cells has been evaluated in
a series of in-vitro studies [33, 34]. Emodin, in a dose of 5 tg/ml
added directly to the media, inhibited the growth of renal
mesangial and tubular cells of human or animal origin, as
0 25 50 100 200 400
Emodin concentration, pig/mI
Fig. 6. Effect of different Concentrations of emodin on rat glomerular
mesangial cell proliferation.
evidenced by a decreased uptake of 3H-TdR, 3H-UR, and 3H-Leu
of the cultured cells (Fig. 6). These effects were dose dependent,
and the suppression was reversed when the drug was removed
from the culture medium [33]. Cells treated with emodin were still
alive, as evidenced by vital stain studies. Serum obtained from rats
that had ingested extracts of rhubarb (containing emodin) also
were observed for their effects on cell growth; such sera also
suppressed the growth of both mesangial and tubular cells [35].
The peak of suppressive effect of their sera appeared 6 hours after
oral administration and gradually tapered off until 16 hours post
administration. The time course of suppressive effects on renal
cells coincided with the levels of emodin and rhein detected
H COOH
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Fig. 5. Basic structure of anthraquinone.
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sequentially in the serum (Fig. 7). We also found evidence that
emodin influenced the cellular metabolism of renal tubular cells.
It decreased the gluconeogenesis of tubular cells and diminished
the ATP content of epithelial mitochondria. Both the Na/K-
ATPase and Ca tATPase activities of the epithelial cell were
attenuated during the administration of emodin in an in-vitro
study [19] (unpublished observations).
To explore the possible molecular mechanism of the action of
emodin on cellular growth, we assessed its effect on the expression
of c-myc mRNA in cultured rat mesangial cells by dot blot
hybridization [36]. Mesangial cells (2 X 10) made quiescent by
exposure to a defined serum-free medium were used in the
experiment. The addition of lipopolysaccharide (10 jsg/ml) re-
sulted in a high level of expression of the c-myc mRNA within 30
minutes and persisted for 6 hours. Interestingly, such induction
could be inhibited promptly by the addition of emodin (25 j.tg/ml)
within 30 minutes; this effect peaked at 2.5 hours. Thus emodin's
inhibitory action on renal cell growth might be mediated, at least
in part, via downregulation of c-myc mRNA overexpression. To
ascertain the role of emodin on cell cycle regulation, we used
immunohistochemical methods to perform a quantitative analysis
of the expression of PCNA in cultured rat mesangial cells [371.
Emodin inhibited the expression of PCNA in mesangial cells, and
the number of S-phase cells was decreased profoundly when
emodin was added to the medium. These results are consistent
with the presumption that the inhibitory action on c-myc mRNA
expression, and hence cell cycle downregulation, might be the
reason why emodin inhibits mesangial cell proliferation. Our
study on the effect of emodin in the proliferation of the SV4O cell
line also supported this concept. The growth of the SV4O cell line,
a mesangial cell from SV4O transgenic mice with extraordinarily
rapid growth, was noticeably inhibited when emodin was added to
the culture media. 3H-thymidine uptake of the specimen when 5
jsg/ml of emodin had been added was 42,007 8707 cpm/well as
compared with the control of 81,030 2230 cpm/well (P < 0.01).
Its suppressive effect was dose dependent; when the concentration
of emodin reached 10 pg/mI, the growth of cells was totally
suppressed [38].
Number of hillocks/wells
Control (n = 6) 172 17
Emodin (jLg/ml)
5 (n=4) 159±10
10 (n=4) 65±5.5a
20 (n=4) 32±3.5k'
Table 5. Fibronectin in supernatants of cultured human mesangial cells
after exposure to emodin
Fibronectin in
supernatants (ng/ml)
Control (n = 10) 2.44 0.65
Emodin (pg/mi)
5 (n = 10) 2.02 0.31
10 (n = 10) 1.04 0.06a
20 (n = 10) 0.25 o.1o'
The effect of emodin in inhibiting the production of fibronectin
(Fn) in cultured mesangial cells has been examined. Secretion and
deposition of En in human mesangial cells (hMC) were deter-
mined by ELISA and immunofluorescence staining techniques.
Hillock formations (an in-vitro sclerotic model) made by conflu-
ently cultured hMC were detected, counted, and photographed
under microscopy. Emodin dose dependently inhibited hMC
proliferation and delayed and lessened the formation of hillocks
(Table 4). The amount of Fn in the supernatants of hMC
decreased significantly after exposure to emodin, as shown in
Table 5. Fn deposition in emodin-treated cells with or without
TGFI3 stimulation was also significantly lessened, as shown by
both ELISA assay and immunofluorescence staining. In short,
emodin not only inhibits mesangial cell proliferation, but it also
decreases extracellular matrix production.
In recent studies we have shown that rhubarb also suppressed
the production of various cytokines from macrophages and hu-
man mesangial cells [39, 401. The production of IL-i from human
macrophages stimulated by LPS in vitro was downregulated by
emodin. Similarly, emodin also reduced the release of IL-6 from
human mesangial cells stimulated by LPS in vitro. IL-6 induces
the expression of c-myc mRNA in mesangial cells, but in the
presence of emodin, the IL-6-induced c-myc mRNA expression
was suppressed [40]. These experimental studies led us to postu-
late that the suppressive effect of emodin on proliferation of
mesangial cells could be mediated via many pathways, including
direct inhibition of c-myc expression, an indirect effect via down-
regulating IL-6, or other unknown events relevant to cell cycle
maturation. Experiments on SV4O cells revealed that the inhibi-
tory action of emodin on c-myc mRNA expression was cyclohex-
imide independent. Emodin also could suppress the production of
TNF by macrophages originating in the peritoneal cavity of rats.
The amount of TNF produced by macrophages in vitro under the
direct addition of emodin or sera of rats that had ingested extracts
of rhubarb was decreased from 70% 6% of the control to 45%
1% or 36% 2%, respectively (P < 0.01) [39].
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Table 4. Effect of emodin on mesangial cell hillock formation
a Versus control, P < 0.01.
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Fig. 7. Blood Concentration of emodin after a single oral dose (100 mg/kg)
of rhubarb in the rat. Symbols are: (U) total; (LI) rhein; (•) aloe-emodin;() emodin.
a Versus control, P < 0.01.
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A B C D
Group B
n=35 Group Cn31 Group Dn=31
BP, Kpa 21.3 2.7 16.16 1,97b 20.6 1.68
Cholesterol, mmol/L 3.26 Q7 3.36 0.8 4.26 0.89
Triglyceride, mmol/L 1.51 0.42a 1.62 0.41 2.06 0.51
HDLch, mmol/L 1.44 0.31a 1.19 0.41 1.10 0.18
LDLch, mmol/L 1.18 0.35a 1.35 0.31 2.06 0.4
VLDLch, mmol/L 0.61 0.32a 0.67 0.30 0.84 0.35
In-vivo studies of rhubarb
Using 5/ nephrectomized rats as the animal model of chronic
renal failure, we performed a series of experimental studies in
Sprague-Dawley male rats [41, 42]. Experimental therapy started
4 weeks after partial nephrectomy, and the study medication was
administered for 12 weeks. Observation lasted for a total of 16
weeks. Animals were divided randomly into 4 groups. Group A
comprised the normal controls; Group B animals were /6 ne-
phrectomized and treated with extracts of rhubarb, 25 mg/kg/day;
Group C animals were nephrectomized and treated with
enalapril, an angiotensin-converting-enzyme inhibitor; and in
Group D, animals were /6 nephrectomized but received neither
rhubarb nor enalapril. The survival rate of Group D (not treated)
at the end of observation was 61%, Group C (enalapril) 71%, and
Group B (rhubarb) 75%. A significant statistical difference (P <
0.05) existed between Groups D and B. The survival rate of the
rats treated with rhubarb was much better than that of the
untreated group. The serum creatinine level of the ¾ nephrecto-
mized animals rose at week 4 after the nephrectomy and reached
its peak at week 16. The Scr values were 2.15 0.76 mg/dl, 2.48
0.54 mg/dl, and 3.08 0.64 mg/dl for groups B, C, and D
respectively. Rats treated with rhubarb (Group B) or enalapril
(Group C) had a lower level of serum creatinine than did group D,
particularly at the 16th week (Fig. 8). The BUN levels in the 4
groups of experimental animals presented a similar pattern of
change as that for serum creatinine. The BUN level of the group
of rats treated with rhubarb was significantly lower than that in the
group treated with enalapril (P < 0.05). The blood chemistry of
the animals of different groups differed little, except that the
serum potassium level of the enalapril group (6.93 0.93
Group B Group C
n=35 n=31 Group Dn=31
Body weight, g 359.6 41.7 368.2 54.3
Kidney weight, g 2.75 0.63' 2.94 0.55
KW/BW 7.52 1.11" 7.88 0.84
Remnant kidney
Protein, mg 166.3 18.2" 178.2 23.4
RNA, mg 4.26 0.22" 4.48 1.37
DNA, mg 3.98 0.33 3.95 0.29
366.3 57.2
3.01 0.44
8.11 0.44
182.4 29.6
4.77 0.55
4.05 0.52
Versus Group D, ap < 0.05, bp < 0.01.
Table 8. Remnant kidney oxygen consumption
Group B Group C
n=10 n=10 Group Dn=10
Basal oxygen consumption
(uinol/min/g) 2.13 0.31 2.48 0.28a
Estimated nephron oxygen
consumption
(nmol/min/nephron) 0.54 0.08 0.62 0.09"
2.63 0.47a
0.70 006b
mmol/liter) was higher than the rest. Rhubarb and enalapril not
only suppressed the degree of azotemia of the nephrectomized
rats, but also reduced the urinary protein excretion. As expected,
enalapril attenuated the high blood pressure of the experimental
animal; rhubarb had no effect on blood pressure. Unexpectedly,
rhubarb exerted a prominent beneficial effect on the lipid metab-
olism of the uremic rats; total cholesterol and LDL levels were
lowered, and the HDL level rose (Table 6). This effect also might
contribute to the prevention of progression of chronic renal
failure [431.
The experimental animals were sacrificed at the end of 16
weeks. Kidney weight, RNA, DNA, and protein contents of the
renal tissue for each animal were measured. Rhubarb treatment
decreased the kidney weight/body weight ratio and RNA contents
of the renal tissue (Table 7). In other words, it blunted the
hypertrophy of the remnant kidney. An isolated perfusion kidney
(IPK) study was performed at the end of the observation [42]. The
02 consumption of the renal tissue of rats fed rhubarb was
significantly lower than that of the renal tissue of the rats treated
with enalapril or the tissue of the non-treated group, either in
terms of basal 002 or estimated nephron Q02 (Table 8). The
inulin clearance of the nephrectomized rats also improved in
those treated with rhubarb or enalapril. Values of inulin clearance
of the three groups of animals were: Group B, 131 2.25; Group
C, 129 14.8; Group D, 117 13.6 .d/min/g (Group B versus
Group D, P < 0.05). In summary, the experimental study on the
chronic renal failure model of /6nephrectomized rats proved that
rhubarb lowers the BUN and serum creatinine level of the treated
animals, decreases urinary protein excretion, promotes inulin
clearance, attenuates lipid derangement, and decreases °2 con-
sumption and the hypertrophic state of the remnant kidney, but
does not lower the blood pressure of the uremic animal. Overall,
rhubarb retarded the progression of chronic renal failure, its
therapeutic effects being more marked than those of enalapril.
To evaluate the clinical effectiveness of rhubarb, a prospective
Table 7. Body weight, kidney weight, renal protein, and DNA and
RNA contents in animals at week 16 after 5/6 nephrectomy4.O
3.0
I
group
Fig. 8. Effect of rhubarb extract and enalapril on serum creatinine in 5/6
nephrectomized rats. Symbols represent: (i:i1 at week 0; (•) at week 4; (1111)
at week 16.
Table 6. Blood pressure and lipid levels in rats at week 16
after 5/6 nephrectomy
Versus group D; ap < 0.05; bp < 0.01.
Versus Group B, a P < 0.05; b P < 0.01; C Versus Group D, P < 0.05.
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Group A Group B Group C
Number 54 61 36
Sex (M/F) 31/23 49/12 22/14
Age, years 46 (24 61) 43 (25 67) 38 (23 58)
Scr, mg/dl 3.73 1.04 3.61 1.16 3.63 0.75
BUN, mg/dl 42.3 12.3 40.0 18.9 41.2 15.9
Underlying renal disease
Glomerulonephritis 36 39 23
Tubulointerstitial 15 18 6
nephritis
Hypertensive 1 2 2
nephrosclerosis
Reflux nephropathy 0 1 2
Uric acid nephropathy 2 1 3
Group A Group B Group C
Slope of 1/Scr —0.002703 —0.002440 —0.003579
(mg/dl/month) —0.001748 —0.00164&' —0.002582
ESRD cases 14/54 8/61 19/36
clinical trial was conducted from 1989 to 1992 in 151 patients with
chronic renal failure. Comparisons were made between the pa-
tients treated either with rhubarb and an ACE inhibitor, as well as
with a combined regimen of rhubarb and the ACE inhibitor
captopril [44—47]. Patients involved in this study had moderate
degrees of CRF; the average value of their serum creatinine was
328 92.8 .tmol/liter (ru 3.7 mg/dl). We used the extract of
rhubarb for patients in Group A, rhubarb and captopril in Group
B, and captopril alone in Group C (Table 9). All the patients
enrolled in the study were followed for an average of 32.5months.
The frequency of end-stage renal failure (Scr 8 mg/dl) by the end
of a 25—40 month followup period was 54.3% for the ACE
inhibitor group, 25.9% for the rhubarb-treated group, and 13.1%
for those receiving a combined regimen. The progressive rate of
decline in renal function was expressed as the slope of the
reciprocal serum creatinine versus the time in months, and the
regression coefficient, the b value, was used to reflect the progres-
sive rate of renal failure (Table 10). The slope of progression was
steepest in the captopril-treated group and more horizontal in
groups A and B (Fig. 9). This finding suggests that the progression
rate of renal failure was slowed in the groups of patients treated
with rhubarb. The body weight of patients before and after
rhubarb treatment did not change much; there were no signs of
undernourishment. As expected, we found increments in both the
plasma albumin and transferrin level, pointing to an improved
nutritional status for the patients after treatment (Table 11).
The BUN level of patients taking rhubarb dropped slightly
during treatment and resulted in a decrease in the BUN/serum
creatinine ratio, much like those that occurred in the animal
experiments. Clinically, rhubarb also lowered the cholesterol and
triglyceride levels of the CRF patients, an effect that might be
helpful in preventing the development of glomerulosclerosis.
This prospective controlled clinical trial suggested that rhubarb
is effective in preventing the progression of CRF and that rhubarb
Group A Group C
Entiy Followup Entry Followup
BW, kg 57.5 10.8 57.3 9.5 57.6 8.2 57.8 9.1
Hb, gIL 93.1 29.7 97.6 21.7 97.1 20.2 100.2 30.1
Alb, gIL 37.1 4.3 42.6 2.9' 38.0 3.1 38.6 2.4
PreAlb, gIL 0.51 0.25 0.50 0.21 0.50 0.24 0.49 0.26
Tf, gIL 1.83 0.58 2.17 0.81 2.01 0.58 1.92 0.81
Ch, mmol/L 5.2 1.1 4.8 0.9a 5.1 1.2 5.0 1.03
TG, mmol/L 1.5 0.6 1.2 0.4" 1.5 0.7 1.4 0.7
VLDLch, mmol/L 0.7 0.2 0.6 0.2a 0.6 0.2 0.6 0.3
HDLch, mmol/L 1.2 0.4 1.3 0.5 1.3 0.5 1.3 0.4
LDLch, mmol/L 3.1 0.7 3.2 0.6 3.2 0.7 3.1 0.6
is more effective than treatment with an ACE inhibitor. Its
immediate effects include the decrease in the BUN level and in
the ratio of BUN/serum creatinine and regression of uremic
symptoms. Long-term followup demonstrates that the progression
rate of CRF is retarded, and that the nutritional status and quality
of life of patients is improved.
Prevention of chronic renal failure
It is widely believed that once there has been sufficient initial
damage, no matter what the cause, renal failure inevitably
progresses [48]. The mechanisms behind this progression have
been the subject of intensive research for many years. The
remnant kidney model, in which both morphologic and functional
alterations occur, has been used extensively in these investiga-
tions. Research has focused on the adaptations that result from
the loss of renal mass, because changes that are maladaptive can
further contribute to renal injuty [49]. These changes include
compensatory renal growth and adjustments in renal hemodynam-
ics, tubular transport, and metabolic activity. The role of glomer-
ular adaptive hemodynamic changes [501, adaptive glomerular
hypertrophy [51], the role of proteinuria, lipids, and the role of
adaptive tubular hypermetabolism [52, 53] are the topics most
frequently discussed. In experimental models of progressive
chronic renal failure, protein restriction has been associated with
a decrease in the elevated nephron glomerular filtration, plasma
flow, and hydrostatic pressure, as well as with a decrease in
Table 9. Clinical presentation at initiation of trial 0.30
0.25
0.20
0.15
;:: 0.10
0.050
Table 10. Mean slope of reciprocal serum creatinine versus time and
the number of patients who reached ESRD during
rhubarb or enalapnil therapy
5 10 15 20 25 30 35 40
Time, months
Fig. 9. Progression rate of renal failure in different therapeutic group.
Symbols are: (LII) ACEI+R; (•) R; (0) ACEI.
Table 11. Blood chemistry of different group patients at entry
and followup
Vs Group C, ap < 0.05; bp < 0.01.
Ch: cholesterol; TG: triglyceride; Tf: transferrin; PreAlb: prealbumin
versus entry; ap < 0.05; bp < 0.01.
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glomerulosclerosis and a reduction in mortality [49, 50]. Subse-
quent studies in the animal model (as assessed by the incidence of
glomerulosclerosis, renal function, and mortality) also demon-
strated that treatment with an ACE inhibitor was as protective as
protein restriction [49, 50].
Considerable argument exists as to whether various interven-
tion strategies based on the experimental studies will prevent or
slow the progression of renal failure in patients. From a series of
reports, including both retrospective and prospective trials, it
became clear that protein-restricted diets could have a beneficial
effect on the course of human renal failure [54, 55]. Yet it has not
been established which dietary regimen should be used, nor when
treatment should be initiated. Recently, based on the MDRD
study [8], a workshop on the "Prevention of Progression in
Chronic Renal Diseases" sponsored by NIDDK developed rec-
ommendations for dietary therapy in the prevention of progres-
sive renal insufficiency in nondiabetic patients [55]. It addressed
the fact that for patients with severe loss of renal function (GFR,
13—25 ml/min/1.73 m2) who adhere to a diet containing 0,6 g
protein/kg/day, the rate of loss of renal function is reduced, and
the time elapsed before reaching end-stage renal disease is
prolonged. Moreover, dietary protein restriction delays the onset
of the uremic symptoms. However, for patients with a moderate
loss of renal function (GFR, 25—55 ml/min/1.73 m2), the evidence
that a prescribed low-protein diet slows the progression of renal
failure is inconclusive. Until definitive information from further
subgroup analyses of the MDRD or data from other studies are
available, a standard protein intake should be prescribed (>0.8
g/kg/day). If there is evidence of progression of renal sufficiency or
the development of uremic symptoms, an intake of 0.8 g/kg!day is
appropriate. As many authors indicated, the protein-restricted
diet frequently was not adequate to maintain normal muscle and
visceral protein metabolism in patients with chronic renal failure.
It was therefore recommended that nutritional status of the
patient be monitored regularly, regardless of the level of protein
intake prescribed, to ensure that patients do not become malnour-
ished. Both body weight and the concentrations of serum albumin
(>4 g/dl) and transferrin (>200 mg/dl) must be maintained.
Patients who lose weight may require an increase in energy intake
from 25 to 30—35 kcal/kg/day.
The possibility that ACE inhibitors retard the progression of
renal disease in humans has received considerable attention in the
last decade [14]. Substantial evidence indicates that adequate
control of hypertension slows the progression of renal disease in
humans [54, 56].
Angiotensin-converting-enzyme inhibitors have been shown to
be effective in reducing blood pressure and urinary protein
excretion in patients with a variety of renal diseases [14, 57]. Some
studies in experimental animals suggest that antihypertensive
agents differ in their protective effects on the kidney, possibly
because they differ in their ability to lower intraglomerular
capillary pressure. Several reports indicate that in rats with
experimental renal disease, ACE inhibitors, but not triple therapy
(reserpine, hydralazine, and hydrochlorothiazide), lower glomer-
ular hypertension and decrease glomerulosclerosis in the remnant
kidney model [58]. But other studies have not found significant
differences in the development of sclerosis in rats with experimen-
tal renal disease treated with ACE inhibitors or triple therapy
[59]. Recently, Lewis et al reported that captopril protects against
deterioration in renal function in insulin-dependent diabetic
nephropathy and is significantly more effective than that seen
when hypertension was similarily controlled by agents other than
ACE inhibitors. In a randomized double-blind study, 207 patients
received captopril and 202 patients received a placebo. Serum
creatinine concentrations doubled in the 25 patients in the
captopril group, as compared with 43 patients in the placebo
group (P = 0.007) [12]. Thus, the results for diabetic renal disease
are conclusive. However, few studies have addressed this potential
preventive therapy in patients with nondiabetic renal functional
impairment. Kamper et al reported an open-label study of 70
patients (including diabetics) with a median GFR of 15 ml/min/
1.73 m2 randomized to treatment with either enalapril or conven-
tional antihypertensive agents, aiming for a blood pressure of
120—140/80—90 mm Hg. They concluded that progression of
moderate to severe chronic nephropathy was slower in the
patients treated with enalapril [60]. Zucchelli and coworkers
compared captopril and nifedipine in an open-label study of 121
nondiabetic hypertensive patients over 3 years; they did not note
a difference in progression rates between patients on the two
drugs, consistent with the hypothesis that both catopril and
nifedipine are renoprotective [56]. Becker and colleagues studied
a group of 70 patients with nondiabetic chronic renal failure,
whose Scr ranged from 2,8—6.8 mg/dl randomly allocated to
receive either enalapril or a placebo, and suggested that the ACE
inhibitor has a favorable effect on the progression of renal failure,
as determined by changes in glomerular filtration rate (measured
by isotopic methods or as creatinine clearance, and reciprocal of
serum creatinine) [54]. The protective effect of enalapril was
independent of blood pressure control. It generally has been
believed that converting enzyme inhibitors could be effective only
when used in the early stages of renal insufficiency. But the data
of Becker et al demonstrated the potential capacity of the ACE
inhibitor to slow the rate of progression of chronic renal failure,
even in patients with very low glomerular filtration rates.
We have completed a randomized controlled study of the effect
of captopril on the progression of chronic renal functional impair-
ment in nondiabetic subjects (unpublished observations). Eligible
patients were aged 20 to 67 years with established renal functional
impairment (serum creatinine, 2.5—5.0 mg/dl). Patients had been
assessed by measurement of serum creatinine at least twice over
the 2 weeks prior to the study without any recognizable reversible
causes of renal function deterioration. Patients were randomly
allocated to receive either captopril (35 patients) or a matching
placebo (24 patients) for up to 48 months. Renal function was
measured using serum creatinine, BUN, and the reciprocal of
serum creatinine. Six of the 35 in the captopril group and 9 of the
24 in the placebo group reached ESRD by the end of the 2-year
observation period; this difference was significantly different at the
P < 0.05 level. Our study clearly showed the positive effect of
captopril, yet its protective effect against progression of renal
impairment seemed to be restricted to those patients with early or
moderate disease and a serum creatinine of 2—4 mg/dl.
The effect of emodin (rhubarb extract) on the prevention of
progression of chronic renal failure is unique because of its
multiple actions on the metabolism of renal tubular and mesangial
cells [15, 42]. Neither the experimental study nor clinical obser-
vation showed any antihypertensive effect of rhubarb. Emodin
attenuated the hypertrophy of the remnant kidneys of partially
nephrectomized animals and also diminished the renal hypertro-
phy that occurred in rats with streptozotocin (STZ)-induced
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diabetes, as recently reported by Yang [61]. Isolated perfusion
studies showed that emodin reduced the oxygen consumption and
gluconeogenesis of remnant kidneys, but did not influence the
glomerular filtration rate. Cell culture studies also demonstrated
that emodin could suppress the growth of renal mesangial and
tubular cells. Its action appears to be mediated mainly through the
inhibition of gene expression of c-myc and the retardation of cell
cycle. In short, the pharmacologic action of emodin is closely
related to its effect on cellular metabolism, and it attenuates the
hypermetabolic state of remnant kidneys. Thus, emodin works
quite differently from ACE inhibitors. The role of adaptive
tubular hypermetabolism in the contribution of progression of
chronic renal failure has been studied by many authors, and
pharmacologic interventions such as calcium-channel blockers,
vitamin E (anti-oxidants), and thyroidectomy [62] have been tried
to reduce the severity of experimental chronic renal failure and
scarring. However, in humans none of these interventions has
yielded any promising effect. Rhubarb, through its unique phar-
macologic action, working mainly on the renal metabolism, did
not exert a marked effect on hypertension, yet it retarded the
progression of chronic renal failure both in experimental animals
and in humans. Of course, its effect might be multifactorial, not
only limited to the reduction of °2 consumption or the prolifer-
ation of renal tubular cells. Its beneficial effect on the alteration of
lipid metabolism of chronic renal disease also might reflect its
unique action on the basal metabolism of cells. Obviously, emodin
deserves further investigation to clarify the therapeutic effect of
this herb.
Both the experimental studies on remnant kidneys and clinical
trials of chronic renal diseases conducted in our institute clearly
showed that the beneficial effect of rhubarb (emodin) on the
prevention of progression of chronic renal disease is more marked
than that of the ACE inhibitors. Although the modes of action of
these two drugs differ, one presumably working largely through
the regulation of glomerular hemodynamics, and the other mainly
via the metabolic pathway, nevertheless they both exert beneficial
effects on the progression of chronic renal failure. Our studies also
clearly demonstrated that their therapeutic effects are additive.
In fact, the progress of chronic renal disease is probably
multifactorial and the factors are cumulative and sequential [54].
Each nephropathogenetic factor probably enters at a different
stage of renal failure, depending on the initial cause of renal
damage and the dominant pathophysiology of the affected
nephrons. As disease progresses, the nephropathogenetic factors
accumulate, each adding to the previous mechanism and each
aggravating the disease process toward end-stage renal failure.
Trials of treatments directed at only one possible factor will need
to focus on whether the relevant factor is being dealt with at its
most critical point for intervention. Furthermore, we doubt that
for each case of ESRD there is only one nephropathogenetic
factor at work. Therefore, a combined therapy with drugs of
various actions and additive effects might be a more reasonable
regimen for the clinical management of ESRD. Currently, com-
bined treatment with rhubarb and an ACE inhibitor seems to be
quite promising. Clearly more research is needed before such a
regimen can be put into routine clinical use.
Questions and answers
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts, USA): Thank
you, Dr. Li, for a Forum of considerable breadth, ranging from the
epidemiology of ESRD in China, one-quarter of the world's
population, to cell-culture studies to clinical trials. Let me begin
the question-and-answer period by asking, what factors account
for the high incidence of glomerular disease in China?
DR. Li: Glomerulonephritis (GN) is the most common cause of
ESRD in China. The incidence of GN in the Chinese population
is around 0.49%, much higher than in Western countries, but
lower than that reported from Africa [63]. As you all know, GN is
a group of diseases closely related to poor sanitation. A high
incidence of infection and environmental pollution favors the
development of this disease. As a developing country, China has
made rapid economic progress in the past decade. Concomitantly,
the incidence of GN in China has decreased, but it is still quite
high as compared with that in Western countries. Within China,
the incidence of GN in different localities varies a great deal,
being higher in less developed northern parts of the country as
compared with the southern region.
As the incidence of GN has decreased in China, the incidence
of diabetic nephropathy has increased. According to surveys
carried out among 300,000 individuals in 14 provinces during the
late 1970s, the incidence of diabetes mellitus was 13.4%. Ten
years later, in 1989/1990, the incidence rose to 24.6%. In another
set of surveys made among 60- to 70-year-olds, the incidence of
diabetes mellitus increased from 64% in 1981 to 125.6% in 1991
(unpublished data). These data demonstrate that the demo-
graphic profile of the causes of ESRD in China is undergoing
change. Over the next several decades, I believe that diabetes
mellitus will replace GN as the most important cause of ESRD in
China.
DR. HARRINGTON: Are there special types of bacterial or
viral-induced glomerulonephritides in certain parts of the coun-
try?
DR. Li: No single microorganism has been identified as the
dominant etiologic agent causing GN in China. The occurrence of
post-streptococcal acute GN is now infrequent due to the wide-
spread use of antibiotics during acute respiratory infection. Hep-
atitis B viral infection is common in China, affecting 10% to 15%
of the population. Once suspected to be an important cause of
GN in China, we now know that it is important only in the
pathogenesis of membranous nephropathy in childhood and in
certain cases of mesangiocapillary GN in adults.
DR. Ross R. BAILEY (Department of Nephrology, Christchurch,
New Zealand): It is of interest that in the Chinese and Japanese,
and I think Indians, IgA nephropathy is much more likely to
present with proteinuria or even the nephrotic syndrome, com-
pared with Caucasoids, in whom microscopic hematuria or per-
sistent urinary abnormalities are the common presentations.
Some groups such as Polynesians, Australians, aborigines, Afri-
cans, and American blacks have a very low incidence of IgA
nephropathy. Do you have any ideas regarding the underlying
genetic aspects of such differences in clinical presentation?
DR. Li: It is really a puzzling question. We had compared the
clinical presentation of IgA nephropathy in Chinese and in
Australian patients [641. We found that the frequency of ne-
phrotic syndrome reached 16.7% in the Chinese group, but it was
only 5% in the Australians. HLA typing in 68 patients with IgA
nephropathy disclosed a significant prevalence of HLA-DR4 in
Chinese patients with this disease; these data resembled those
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collected from Japan but differed from those observed in Cauca-
soids. However, detailed analysis of the clinical manifestations of
individual patients did not show any correlation between the
occurrence of nephrotic syndrome and the specific HLA typing.
One interesting phenomenon I want to mention here is that
Chinese patients with IgA nephritis tend to have a higher fre-
quency of co-existence of IgG and/or 1gM mesangial deposits, as
well as IgA deposits. These patients also have heavier proteinuria
and overt nephrotic syndrome [65]. The underlying mechanism of
this phenomenon is not understood yet.
DR. CLAUDIO PONTICELLI (Director, Division of Nephrology,
Ospedale Maggiore, Milan, Italy): I am impressed by the results of
your clinical trials with rhubarb and would like to have more
information about the trial. Were the renal effects dose depen-
dent? Could you identify a threshold dose of efficacy? What are
the side effects of rhubarb? Did you find any difference in
response between patients with mild renal insufficiency and
patients with more severe renal failure?
DR. Li: The renal effect of rhubarb is dose dependent, at least
in vitro, as shown by our cell-culture study [661. Rhubarb sup-
presses the growth of renal tubular and mesangial cells, and
inhibits the production of fibronectin from the mesangial cell, but
only when the concentration of emodin reaches a certain level.
Clinically, we did not identify the threshold dose of efficacy. As
rhubarb has been used extensively as a traditional remedy for
more than one thousand years, the dose we adapted in clinical
trial is the amount in common use. With this dosage we can detect
emodin in the blood at concentrations that have an effect in vitro.
Rhubarb appears safe in ordinary clinical use. If large doses
beyond the ordinary range are used, it will cause frequent bowel
movements and epigastric discomfort. These symptoms disappear
rapidly when the drug is discontinued. Extensive studies did not
show any toxic effect of rhubarb on the liver, the kidney, or on the
cardiovascular system [671.
We believe that this drug suppresses the hypermetabolic state
of the remnant renal tissue, thus retarding the progression of
chronic renal failure. We also believe that the drug should be
used, and is more effective, when the serum creatinine is at the
level of 2.5 mg/dl. In our hands, whenever the serum creatinine
value of the patient exceeded 7 mg/dl, the therapeutic response to
rhubarb was poor.
DR. K. S. CHUGH (Consultant Nephrologist, National Kidney
Clinic and Research Centre, Chandigarh, India): Published reports
suggest that HBsAg-related glomerular disease is common in
Southeast Asia, particularly Hong Kong and Taiwan [68]. It also
has been reported that the majority of cases of membranoprolif-
erative glomerulonephritis in adults are related to HBsAg [69].
How do you explain the low incidence of HBsAg-related renal
disease in China?
DR. Li: This is an intriguing question. Since the first case
reported by Combes in 1971, hepatitis B virus-related glomerulo-
nephritis has been found by many authors in many countries.
There does appear to be a proven causal relationship between
hepatitis B viral infection and both membranous and membrano-
proliferative glomerulonephritis [701.
We performed a survey of serum markers of hepatitis B viral
infection among 1000 adult cases of glomerulonephritis at the
Jinling Hospital [71]. We found that only the group of patients
with membranous nephropathy and membranoproliferative gb-
merulonephritis showed significantly higher positive rates than
did the average population (that is, 10% to 15%), amounting to
24.6% and 20.0% respectively [71]. However, these two patho-
logic subtypes of glomerular disease are infrequent in China,
comprising only 14.4% of the total cases of glomerulonephritis.
In contrast to these observations, we on the other hand found a
rate of hepatitis B viral infection of only 7.6% in IgA nephropathy,
the most common and important glomerular disease in China. A
causal relationship between IgA nephropathy and hepatitis B viral
infection has been emphasized by some investigators [72]; how-
ever, it has not been widely accepted [73]. lida et a! also have
claimed that IgA nephropathy is unrelated to hepatitis B surface
antigenemia, according to an epidemiologic study carried out in
Japan [74]. Therefore, we believe that there is no firm evidence
that the common types of acute glomerulonephritis in Chinese
adults are etiologically related to hepatitis B viral infection.
DR. NICOLAOS E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): You mentioned
that rhubarb extracts ameliorate proteinuria in the ablation model
of renal failure in the rat without affecting systemic blood
pressure. Do these extracts also affect intraglomerular pressure,
the permeability characteristics of the glomerular basement mem-
brane, or the degree of glomerular sclerosis?
DR. Li: We believe that the impact of rhubarb extracts on the
ablation model of renal failure is mediated mainly through its
influence on the hypermetabolic state of the remnant renal tissue.
After 12 weeks of emodin administration, proteinuria decreased
in the % nephrectomized rats as compared with the experimental
controls (P < 0.01), but hypertension persisted. The inulin
clearances of the treated animals also improved.
I cannot directly answer your question because we did not
perform micropuncture studies to measure intraglomerular pres-
sure in these animals. However, morphometric analysis of the
renal tissue demonstrated that the extent of interstitial sclerosis
was reduced and that the diminution of post-glomerular capillary
space also lessened as compared with the experimental control.
These findings strongly suggest that the reduction of proteinuria
did not result from more extensive renal sclerosis or decreased
glomerular filtration. We presume that the reduction of protein-
uria in the treated animals is due mainly to a decreased state of
hypermetabolism, as I stated before.
DR. JA! PRAKASH (Division of Nephrology, Institute of Medical
Sciences, Banaras Hindu University, Varanasi, India): What specific
components of rhubarb contribute to the prevention of progres-
sion of chronic renal failure?
DR. Li: So far as we know, there is probably not a single
component of rhubarb acting on the renal tissue, nor one mech-
anism acting to prevent the progression of chronic renal failure.
Among the various ingredients isolated, however, emodin seems
to be the most important. Emodin can suppress the proliferation
of mesangial and tubular cells more potently than can other kinds
of anthraquinones such as rhein and aloe-emodin. During the
clinical trial, it was the most conspicuous constituent detected in
the patients' blood.
DR. PRAKASH: Why is ESRD due to diabetic nephropathy less
frequent in China as compared to developed countries and some
developing countries such as India?
DR. Li: I am not sure about the answer to this question. I
suspect there are two reasons. First, type-I diabetes mellitus
(IDDM) is infrequent in China as compared with India, perhaps
because of ethnic reasons. Second, type-Il diabetes mellitus
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(NIDDM) is definitely related to increasing obesity and age. The
incidence of diabetes also tends to increase as a population
becomes more affluent.
DR. ROGER SUYFON (Aga Khan University, Karachi, Pakistan):
My question relates to your clinical trial of rhubarb. Do you have
evidence that captopril is beneficial in the patients receiving other
interventions, such as a low-protein diet? If not, one might argue
that captopril is worsening the progression of ESRD in these
patients and that rhubarb is attenuating this adverse effect. This
could explain at least part of rhubarb's apparent beneficial effect.
DR. Li: We have performed studies of captopril both in humans
and in experimental animals. Patients were allocated into 3
groups: captopril, rhubarb, and dietary control. We found that
either captopril or rhubarb was more effective in preventing
progression of chronic renal failure than was dietary control alone
(unpublished data). We also found that rhubarb was even better
than captopril treatment. We currently prefer a combination of
both rhubarb and captopril to strengthen the therapeutic effect.
DR. HARR1NGTON: Dr. Li, let me ask some specific questions
regarding your clinical trial with rhubarb. First, were the patients
randomized? Second, were you able to measure the GFR directly
using either inulin or iothalamate?
DR. Li: Three clinical trials on the effect of rhubarb on chronic
renal failure have been conducted in our institute. Only one
recent cohort of patients was allocated into different treatment
regimens randomly. The followup period of this prospective
controlled trial is not long enough. The clinical data I presented
today all come from a prospective, open-label trial.
Recent studies have demonstrated that measurements of crc-
atinine clearance in ESRD overestimate the GFR by an average
of 30% [75]. To evaluate renal function in clinical trials of
progressive renal diseases, the GFR is best measured with inulin
or iothalamate. However, these sophisticated methods are not
available for clinical use in China. Our policy has been to assess
changes in renal function from serial changes in serum creatinine
concentration. We realize the drawbacks to this approach.
DR. V. JHA (Assistant Professor of Nephrology, Postgraduate
Institute of Medical Education and Research, Chandigarh): You
showed that rhubarb reduces blood levels of IL-i and IL-6. This
observation suggests that the active ingredient in the drug might
have some similarity to steroids. Have you or others used rhubarb
in other renal diseases, such as acute rejection? Does it have a role
in sepsis in either experimental or clinical studies?
DR. Li: As far as we know, rhubarb structurally and biologically
does not have any similarity to steroids. There are no reports in
regard to the use of rhubarb in the treatment of acute allograft
rejection or sepsis.
DR. THOMAS MATHEw (Professor of Nephrology, Medical College,
Calicut, South India): I have two questions and a comment. First,
does emodin have °2 free-radical scavenging action? Does it have
an effect on TGF or PDGF? Second, what was the cause of
chronic renal failure in the trial cases? Were all types of glomer-
ular disease included or only IgA nephropathy? The patient under
discussion had a creatinine clearance of 13 mI/mm, which really is
not indicative of end-stage renal disease. Perhaps there were some
remaining nephrons that would have responded to emodin.
DR. Li: We did not investigate the free °2 radical scavenging
action of rhubarb on renal tissue. Studies on diabetic rats showed
that rhubarb downregulates the glomerular mRNA expression of
PDGF-/3 and TGF/3 [76]. It was presumed that this downregula-
tion might be related to the suppressive effect of rhubarb on renal
hypertrophy of diabetic rats. It is not clear whether these down-
regulating effects of rhubarb on growth factors are primary or
simply secondary to other pathophysiologic change.
The aim of our prospective clinical trial with rhubarb is to
prevent the progression of chronic renal failure, not to reverse
renal sclerosis or to replace the diseased nephron. Thus, patients
enrolled in the clinical study should have some remaining func-
tioning nephrons so that they can respond to rhubarb treatment.
The cause of the renal disease in this group of patients varied,
including several different kinds of glomerulonephritis and inter-
stitial nephritis.
DR. ALEX DAVISON (Consultant Renal Physician, St. James's
Hospita4 Leeds, UK): The clinical trial suggests that the effect of
rhubarb is not alteration of mesangial-glomerular inflammation or
proliferation but rather alteration of hemodynamics. Have you
done any studies on the effects of rhubarb on renal, particularly
intrarenal, hemodynamics?
DR. Li: Our experimental studies clearly showed that rhubarb
suppresses the proliferation of mesangial cells and attenuates the
hypertrophy of the remnant kidney. We believe that it retards the
progression of chronic renal failure mainly through its action on
the hypermetabolic state of the remnant kidney. Currently, we
don't have any evidence pointing to a renal hemodynamic action
of rhubarb for its therapeutic effect.
DR. DAvisoN: Did the urinary protein excretion diminish?
DR. Li: In both experimental trials using /6 nephrectomized rats
or rats in which diabetes had been induced by the injection of
STZ, rhubarb decreased the level of proteinuria but did not
decrease the blood pressure. As the decrement in proteinuria was
closely related to the reduction of kidney size and 02 consump-
tion, rhubarb's effect on proteinuria seems to be related to
structural change, reduction in the size of the kidney, and a
lowered state of metabolism.
DR. MADIAS: In view of the strong antiproliferative effects of
emodin on glomerular mesangial cells, are there any observations
on its effects on the proliferation of vascular smooth muscle cells
or malignant cell lines?
DR. Li: It is an interesting question. Our group did not make
any observations on the anti-tumor effect of rhubarb, but some
Chinese workers have evidence that emodin suppresses the
growth of melanoma cells and a pulmonary carcinoma cell line
A-549 in vitro [77]. Emodin could inhibit the DNA synthesis of
these cells. We do not have any information in regard to the
antiproliferative effect of rhubarb on vascular smooth muscle
cells.
DR. MADIAS: Have you had the opportunity to examine the
effects of emodin on the growth-factor-activatable NatH ex-
changer, that is, NHE-1, of the glomerular mesangial cell? As you
know, the NHE-1 plays an important role in cellular growth and
proliferation [78]. Moreover, decreased cholesterol, which evi-
dently results from the administration of emodin, decreases the
activity of the NHE-1 [79].
DR. Li: The molecular mechanism of the suppressive effect of
emodin on renal cells is not clearly understood yet. I suspect that
emodin might work through many factors. It is possible that the
growth-factor-activatable Na/H exchanger NHE-1 might be
involved in this process. We have found that emodin diminished
both the Na-K ATPase and Ca-ATPase activities of the
epithelial cell [80].
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DR. R. VIJAYAKUMAR (Assistant Professor of Nephrology, Madras
Medical College, Madras, Tamil Nadu, India): Since IgA nephrop-
athy is the most common cause of end-stage renal disease, would
you consider using rhubarb in patients with IgA nephropathy with
nephrotic syndrome or mild renal failure? What is the natural
history of IgA nephropathy in China?
DR. Li: Indeed, our clinical trials with rhubarb involved many
patients with IgA nephropathy, but our aim was to prevent the
progression of chronic renal failure, not to ameliorate the ne-
phrotic syndrome. The prognosis of IgA nephropathy in Chinese
patients obviously varies with individual cases. But overall it is an
indolent chronic nephritis that can progress slowly to chronic
renal failure, as has been described elsewhere in the world.
DR. MAJOR U.K. SHARMA (Command Hospital, Eastern Com-
mand, Calcutta, India): You mentioned that use of rhubarb
(Rheum officinale) decreases cell proliferation and fibronectin
production. Do you have any morphometric data, such as esti-
mated renal mass or length of kidneys before and after treatment
with rhubarb?
DR. Li: Yes. In both the ablation model and the STZ-induced
diabetes model, the size and weight of the kidneys of the
rhubarb-treated animals were markedly reduced as compared
with the experimental controls.
DR. MADIAS: I would like to return to your statement that
dialysis and transplantation in China are primarily offered to some
government employees and officials of private enterprises. Is this
because these individuals have better medical insurance coverage
compared with the rest of the population, or because they have
better access to specialized medical centers?
DR. Li: Yes, there are differences in medical insurance for
different groups of people. For instance, for government employ-
ees, their medical coverage is better and usually includes opera-
tions, transplantation, dialysis, etc.
DR. K. TRIPATHI (Varanasi, India): First, what is the action of
rhubarb on the hydraulic permeability of the basement mem-
brane? Second, does it affect urine output? We presented a paper
at the International Symposium on Diabetic Nephropathy in
Nanjing in 1993 on one Indian herb, Boerhavia diffusa linn,
showing that it increases the hydraulic permeability of the gb-
merular basement membrane and that it also increases urinary
output in patients with diabetic nephropathy.
DR. LI: Experimental and clinical trial data did not show any
diuretic effect of rhubarb in patients with chronic renal failure.
We did not measure the hydraulic permeability of the gbomerular
basement membrane. But judging from the fact that rhubarb
attenuated renal hypertrophy in diabetic rats and that the GFR
was not greatly changed after the administration of rhubarb, it
does not seem likely that the hydraulic permeability of the GBM
is increased.
DR. PRADEEP ARAR (Associate Professor of Nephrology, Luc-
know, India): You suggested that rhubarb acts by decreasing
tubular hypermetabolism. Have you studied its role in the pro-
duction of ammonia and reactive oxygen molecules?
DR. Li: We did not study the influence of rhubarb on the
production of ammonia and reactive oxygen species in the renal
tissue. But in one recent experiment, we found that there was a
tendency for the malonaldehyde contents of renal tissue to be
reduced after rhubarb treatment (unpublished data).
DR. MADIAS: Given the relatively low representation of hyper-
tensive nephrosclerosis as a cause of end-stage renal disease in
China, could you give us some general information on the
epidemiology of hypertension in China? Namely, what is the
prevalence of hypertension in young adults? Does the prevalence
of hypertension increase as a function of age? Are there data on
what fractions of the hypertensive population are treated and
controlled?
DR. LI: As a whole, the prevalence of hypertension in China is
much lower than that of the Western countries. It has increased in
the last 10 years, however. Surveys made in the 1980s reported
that the prevalence of hypertension among the general population
of northern China was only 5.8% for adults above 20 years and
7.9% for adults over 40. A recent report showed that the
prevalence of hypertension has increased to 10% to 15% for
residents of large cities [81].
The regimen of treatment for hypertension in China is similar
to that in the Western countries. Beta-blockers, ACE inhibitors,
and calcium-channel blockers are in common use. Of course,
Chinese herbs are also frequently used by some patients. We need
to study their effects more rigorously.
Reprint requests to Dr. L. Li, Research Institute of Nephrology, Jinling
Hospita4 305 East Zhong Shan Road, Nanjing 21002, P.R. China
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